The CRN Foundation's report, “Supplements to Savings: U.S. Health Care Cost Savings from the Targeted Use of Dietary Supplements, 2022–2030,” provides evidence that the use of certain dietary supplement ingredients by specific populations can reduce the direct and indirect medical costs associated with chronic diseases and conditions—including coronary artery disease.
See the chapters on select supplements and coronary artery disease:
Target population and preventive intake levels
Did you know?
In 2022, FDA announced a qualified health claim for products containing magnesium for reduction of blood pressure.
In addition, FDA permits the use of claims for omega-3 fatty acids and reduced risk of coronary heart disease and hypertension.
